Evidence & regulatory context
- Mechanism
- Human iPSC-derived neural progenitors on laminin-coated pHEMA-MOETACl hydrogel; cell-biomaterial construct.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryCompressionWistarMalen = 30 rats: hydrogel n=10, iPSC-NP seeded hydrogel n=11, salin…Surgical implantation into the spinal cord lesion cavity after laminectomy and glial scar resectionCells seeded on hydrogel samples of approximately 3 x 3 x 3…5 weeks after lesion induction
Model: Balloon compression spinal cord injury at Th8-9 using a 2-French Fogarty catheter balloon inflated with 15 ul for 5 min; treated in the chronic phase after MRI-guided glial scar resection
The cell-polymer construct integrated into the chronic lesion, reduced cavitation, supported progenitor survival for 28 weeks and increased host tyrosine hydroxylase-positive fibre sprouting, but produced no significant improvement in locomotor or thermal nociceptive outcomes.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.